Beam Therapeutics: Peers

The FY2025 (Dec) proxy of Beam Therapeutics names 16 peer companies for pay. Among Beam Therapeutics and these peers, CEO pay was 3rd highest of 5 and total shareholder return was 4th highest of 5.

3rd highest of 5in Beam Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:

$4.8M$14.9M

4th highest of 5in Beam Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:

$20$108

Pay peer group, FY2025 (Dec) proxy

BridgeBio Pharma
CRISPR Therapeutics AG
Agios Pharmaceuticals
Denali Therapeutics
Apellis Pharmaceuticals, Inc.Not disclosedNot disclosed
Arcellx, Inc.Not disclosedNot disclosed
Arrowhead PharmaceuticalsNot disclosedNot disclosed
Blueprint Medicines CorporationNot disclosedNot disclosed
Editas Medicine, Inc.Not disclosedNot disclosed
ImmunityBio, Inc.Not disclosedNot disclosed
Intellia Therapeutics, Inc.Not disclosedNot disclosed
Iovance Biotherapeutics, Inc.Not disclosedNot disclosed
Prime Medicine, Inc.Not disclosedNot disclosed
Rocket Pharmaceuticals, Inc.Not disclosedNot disclosed
Sana Biotechnology, Inc.Not disclosedNot disclosed
Verve Therapeutics, Inc.Not disclosedNot disclosed
16 companies

Changes by year

No proxy on file names a change to the peer group.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.